Spots Global Cancer Trial Database for metastatic breast cancer ( her2 negative)
Every month we try and update this database with for metastatic breast cancer ( her2 negative) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer | NCT01268150 | Locally Recurre... Metastatic Brea... | Eribulin mesyla... | 18 Years - | Eisai Inc. | |
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer | NCT01268150 | Locally Recurre... Metastatic Brea... | Eribulin mesyla... | 18 Years - | Eisai Inc. |